Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;39(9):991-1003.
doi: 10.1007/s10654-024-01146-0. Epub 2024 Sep 18.

Reevaluating the fraction of cancer attributable to excess weight: overcoming the hidden impact of prediagnostic weight loss

Affiliations

Reevaluating the fraction of cancer attributable to excess weight: overcoming the hidden impact of prediagnostic weight loss

Fatemeh Safizadeh et al. Eur J Epidemiol. 2024 Sep.

Abstract

Objective: To evaluate the magnitude of the potential underestimation of the proportion of cancer cases attributable to excess weight, known as population attributable fraction (PAF), due to potential bias from prediagnostic weight loss already present at baseline of cohort studies and to overcome it as much as possible.

Methods: Data from the UK Biobank cohort participants aged 40-69 without prior cancer diagnosis were analyzed. We assessed the magnitude of associations of excess weight with the incidence of obesity-related cancers combined, and separately for gastrointestinal (GI) and other cancers. Using multivariable Cox proportional hazards models, hazard ratios (HR) and their 95% confidence intervals (CI), and PAFs for excess weight at baseline were estimated for various periods of time after weight measurements.

Findings: Of 458,660 participants, 20,218 individuals developed obesity-related cancers during a median 11.0-year follow-up, comprising 8,460 GI, and 11,765 non-GI cancers. PAFs were much higher for cancers occurring more than four years after recruitment than for cancers occurring within the initial four years: 17.7% versus 7.2%, 21.4% versus 11.7% for GI, non-GI and all obesity-related cancers combined, respectively. With respect to total cancer (including cancers with no established relationship with excess weight), PAFs were estimated as 5.1% and 8.8% for the 0-4 and 4-14-year periods of follow-up.

Conclusion: The proportion of cancers attributable to excess weight is likely substantially larger than previously estimated based on cohort studies with short follow-up time or no or only limited exclusion of the early years of follow-up from the analyses.

Keywords: Body mass index; Cancer; Obesity; Overweight; Population attributable fraction.

PubMed Disclaimer

Conflict of interest statement

Authors have no conflict of interests to disclose.

Figures

Fig. 1
Fig. 1
Study population flow diagram
Fig. 2
Fig. 2
Percentage of total cancer, all, gastrointestinal (GI), and non-GI obesity-related cancers attributable to overweight and obesity with including 0–4, 0–14 (complete), and >4–14 years of follow-up

Similar articles

References

    1. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and Cancer–viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–8. 10.1056/NEJMsr1606602. - PMC - PubMed
    1. Continuous Update Project Expert Report 2018. Body fatness and weight gain and the risk of cancer: World Cancer Research Fund/American Institute for Cancer Research; 2018. Available from: https://www.wcrf.org/wp-content/uploads/2021/01/Body-fatness-and-weight-...
    1. Renehan AG, Soerjomataram I. Obesity as an Avoidable cause of Cancer (attributable risks). Recent Results Cancer Res. 2016;208:243–56. 10.1007/978-3-319-42542-9_13. - PubMed
    1. Sung H, Siegel RL, Torre LA, et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin. 2019;69(2):88–112. 10.3322/caac.21499. - PubMed
    1. Renehan AG, Soerjomataram I, Tyson M, et al. Incident cancer burden attributable to excess body mass index in 30 European countries. Int J Cancer. 2010;126(3):692–702. 10.1002/ijc.24803. - PubMed